- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Tryptamine Therapeutics Ltd (TYP)
Tryptamine Therapeutics Ltd stock price live, this page displays ASX TYP stock exchange data. View the TYP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Tryptamine Therapeutics Ltd real time stock price chart below.
What Is the Tryptamine Therapeutics Ltd Stock Price Today?
The Tryptamine Therapeutics Ltd stock price today is 0.038.
What Is the Stock Symbol for Tryptamine Therapeutics Ltd?
The stock symbol for Tryptamine Therapeutics Ltd is ""TYP.""
What Stock Exchange Does Tryptamine Therapeutics Ltd Trade On?
Tryptamine Therapeutics Ltd is listed and trades on the Sydney stock exchange.
Is Tryptamine Therapeutics Ltd a Good Stock to Buy?
Determining whether Tryptamine Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TYP quote. (ISIN: AU0000331993)
What Is the Tryptamine Therapeutics Ltd Stock Price Today?
The Tryptamine Therapeutics Ltd stock price today is 0.038.
What Is the Stock Symbol for Tryptamine Therapeutics Ltd?
The stock symbol for Tryptamine Therapeutics Ltd is ""TYP.""
What Stock Exchange Does Tryptamine Therapeutics Ltd Trade On?
Tryptamine Therapeutics Ltd is listed and trades on the Sydney stock exchange.
Is Tryptamine Therapeutics Ltd a Good Stock to Buy?
Determining whether Tryptamine Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TYP quote. (ISIN: AU0000331993)
Sydney
Currency in AUD
0.038
-0.001(-2.56%)
Delayed Data·
Fair Value
An estimate of a Tryptamine Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.038
0.040
52 wk Range
0.019
0.057
TYP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Tryptamine Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0380.040
52 wk Range
0.0190.057
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
TYP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Tryptamine Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Tryptamine Therapeutics Ltd Company Profile
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
Compare TYP to Peers and Sector
Metrics to compare | TYP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTYPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.5x | −5.6x | −0.7x | |
PEG Ratio | −0.14 | −0.05 | 0.00 | |
Price/Book | 9.4x | 5.2x | 2.6x | |
Price / LTM Sales | 35.5x | 16.0x | 3.4x | |
Upside (Analyst Target) | - | 156.8% | 37.6% | |
Fair Value Upside | Unlock | −4.3% | 5.3% | Unlock |
Earnings
Latest Release
Jul 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Tryptamine Therapeutics Trade On?
Tryptamine Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.
What Is the Stock Symbol for Tryptamine Therapeutics?
The stock symbol for Tryptamine Therapeutics is "TYP."
What Is the Tryptamine Therapeutics Market Cap?
As of today, Tryptamine Therapeutics market cap is 54.72M.
What Is Tryptamine Therapeutics's Earnings Per Share (TTM)?
The Tryptamine Therapeutics EPS (TTM) is -0.00.
When Is the Next Tryptamine Therapeutics Earnings Date?
Tryptamine Therapeutics will release its next earnings report on 15 Oct 2025.
From a Technical Analysis Perspective, Is TYP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Tryptamine Therapeutics Stock Split?
Tryptamine Therapeutics has split 1 times.
How Many Employees Does Tryptamine Therapeutics Have?
Tryptamine Therapeutics has 0 employees.
What is the current trading status of Tryptamine Therapeutics (TYP)?
As of 16 Oct 2025, Tryptamine Therapeutics (TYP) is trading at a price of 0.038, with a previous close of 0.04. The stock has fluctuated within a day range of 0.038 to 0.040, while its 52-week range spans from 0.019 to 0.057.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.